[Management of postoperative inflammatory response and XXXX with nimesulide after cardiac surgery].

@entity1 @entity650 @entity227 @entity260 @entity134 @entity1623 @entity158 @entity9859 @entity3840 @entity1851
INTRODUCTION: Nimesulid (Mesulid) is a non- @entity134 anti-inflammatory drug (NSAID), acting by the selective inhibition of the @entity3840 ( @entity3840 ) isoenzyme. In this study the efficacy of nimesulid following cardiac surgery has been investigated in comparison with that of a @entity9859 isoenzyme inhibitor drug. @entity1 AND METHODS: 200 cardiac surgical @entity1 operated on cardiopulmonary bypass have been involved in this prospective study. 100 @entity1 received 100 mg. nimesulid bd. routinely in the postoperative period (group M). Another 100 @entity1 were given 275 mg @entity1623 bd. (group A). In both groups the White Blood Cell (WBC), the blood sedimentation (We), the @entity1851 ( @entity1851 ) levels were determined from venous blood samples before the operation and on the first five postoperative days. Venous blood samples of 20 @entity1 of each group in the same period were used to determine the @entity650 ( @entity650 ), and the Soluble Tumour Necrosis Factor Receptor-I (sTNF-RI) levels. @entity260 related to the use of the investigated drugs as well as the side effects have been compared in the two groups. A visual analogue @entity158 scale was used before and after drug administration. Kruskal Wallis and student t tests were used for the statistical analysis. RESULTS: No serious complication related to the use of the investigated drugs has developed in either group. In group A gastrointestinal side effect were recorded in 7 cases (7%) whilst in group M no such complaints were found. Drug doses defined in the study protocol had to be raised or another drug had to be added in 11 and 3 cases in group A and M respectively. Neither the laboratory findings, nor the @entity227 scale results have not shown any significant difference between the groups. CONCLUSION: The efficacy of nimesulid in postoperative inflammatory inhibition and @entity158 relief has proved equal to that of the investigated @entity9859 inhibitor drug, however less gastrointestinal side effects have been related to its administration.
